Medical Marijuana, Inc. Investment Firm AXIM ® Biotechnologies Files Patent for Special Early Detection Cancer Biomarker

Medical Marijuana, Inc. Investment Firm AXIM ® Biotechnologies Files Patent for Special Early Detection Cancer Biomarker

SAN DIEGO, Might 21, 2020/ PRNewswire/– Medical Cannabis, Inc.( OTC: MJNA) (the “Company”), the first-ever publicly traded marijuana company in the United States that launched the world’s first-ever cannabis-derived nutraceutical items, brands and supply chain, revealed today that Sapphire Biotech, Inc.(” Sapphire”), a subsidiary of its investment company AXIM ® Biotechnologies, Inc.(OTCQB: AXIM) (” AXIM ® Biotech” or “AXIM”), has actually filed an utility patent application relating to an unique biomarker for the detection of cancer in blood serum and urine.

” Sapphire has actually already shown itself to be an important member of the Medical Marijuana, Inc. family through its excellent clinical discoveries in such little time,” stated Dr. Stuart Titus, CEO of Medical Cannabis, Inc. “We look forward to seeing the business’s continued success in developing ingenious diagnostic tools.”

The patent application is based on Sapphire’s discovery of the long splice version of the enzyme, quiescin sulfhydryl oxidase (QSOX1-L), as a biomarker in bladder cancer patients’ sera that was extremely particular for the existence of cancer and was low or non-existent in regular donors’ sera. This is the first time that a clinically relevant QSOX1-L splice variation has actually been identified as an unique biomarker of bladder cancer and other cancers in serum.

Sapphire researchers have produced a novel antibody that selectively detects just this splice variation and have actually utilized the biomarker to develop a prototype quick and cost-effective diagnostic test for bladder and other cancers non-invasively. On August 21, 2019, a 1 year scientific trial started to examine Sapphire’s test to detect the QSOX1 biomarker in clients with or at danger for pancreatic cancer.

” By making it possible for detection with a basic blood test and supplying a crucial tool for oncologists to evaluate the treatment procedure for clients, Sapphire’s diagnostics items have the prospective to alter the way in which cancer is detected and dealt with,” stated AXIM ® Biotech CEO John W. Huemoeller II.

For more information about AXIM, please visit www.aximbiotech.com

About AXIM ® Biotechnologies
Established in 2014, AXIM ® Biotechnologies, Inc. (AXIM) is a vertically integrated oncology company establishing diagnostic tests for the early detection of cancer, exclusive little molecules drugs not only to deal with cancer but also to obstruct transition and establishing novel antibodies for healing and diagnostic usages. AXIM is likewise developing new cannabinoid molecules for oncological therapies.

Currently, Sapphire Biotech, Inc.’s diagnostic tool is being utilized to study the company’s enzyme biomarker to discover pancreatic cancer earlier than flowing growth cells. Discover more here. For additional information, please visit www.AXIMBiotech.com

About Medical Cannabis, Inc.
We are a company of firsts ®. Medical Cannabis, Inc.( MJNA ) is a cannabis business with three distinct business systems in the non-psychoactive cannabinoid space: a worldwide portfolio of cannabinoid-based nutraceutical brands led by Kannaway ® and HempMeds ®; a leader in sourcing the highest-quality legal non-psychoactive cannabis items originated from industrial hemp; and a cannabinoid-based medical research study and botanical drug development sector led by its pharmaceutical investment companies and partners consisting of AXIM ® Biotechnologies, Inc and Kannalife, Inc Medical Cannabis, Inc. was named a top CBD producer by CNBC Medical Cannabis, Inc. was also the first business to get historical import allows for CBD items from the federal governments of Brazil, Mexico, Argentina, and Paraguay and is a leader in the advancement of international markets. The company’s flagship item Real Scientific Hemp Oil has been used in numerous successful scientific research studies throughout Mexico and Brazil to comprehend its safety and effectiveness.

Medical Marijuana, Inc.’s headquarters is in San Diego, California, and extra details is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com To see Medical Cannabis, Inc.’s corporate video, click here

Shareholders and customers are also motivated to purchase CBD oil and other products at Medical Marijuana, Inc.’s shop.

FORWARD-LOOKING DISCLAIMER
This news release might consist of particular forward-looking statements and info, as specified within the meaning of Section 27 A of the Securities Act of 1933 and Area 21 E of the Securities Exchange Act of 1934, and undergoes the Safe Harbor created by those sections. This material includes statements about predicted future occasions and/or financial results that are positive in nature and subject to risks and unpredictabilities. Such positive statements by meaning include dangers, unpredictabilities and other aspects, which might cause the real results, efficiency or achievements of Medical Marijuana, Inc. to be materially various from the declarations made herein.

FDA (FDA) DISCLOSURE
These declarations have not been evaluated by the Food and Drug Administration. This item is not meant to identify, treat, treat, or avoid any illness.

LEGAL DISCLOSURE
Medical Cannabis, Inc. does not offer or disperse any items that remain in infraction of the United States Controlled Substances Act.

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600
[email protected]
www.cmwmedia.com

Financier Relations Contact:
P. (858) 283-4016
[email protected]

Cision

Cision

View initial content: http://www.prnewswire.com/news-releases/medical-marijuana-inc-investment-company-axim-biotechnologies-files-patent-for-unique-early-detection-cancer-biomarker-301063178 html

SOURCE Medical Marijuana, Inc.

CBD Oil, 9 Life-saving Tips About Cannabinoid
Find Out More